Mike Sherman, Chairman

Mr. Sherman was named Chairman of the Board in August 2023. Prior to this role, Mr. Sherman was the Chief Executive Officer of Chimerix since 2019. Before joining the Company, he served as Chief Executive Officer of Endocyte and led it from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018. Mr. Sherman repositioned the company by re-prioritizing the pipeline, acquiring an external asset, and aggressively executing a phase 3 regulatory and clinical strategy. He joined the company in 2006 and as Chief Financial Officer and Chief Operating Officer and was instrumental in Endocyte’s IPO and four subsequent financings. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including senor staff positions for the European and US operations of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth, graduating as a Tuck Scholar. Mr. Sherman currently serves on the Board of Directors at Werewolf Therapeutics, Inc. He also served on the Boards of Directors at Biospecifics Technologies, Inc. until the company’s acquisition by Endo Pharmaceuticals, Mead Johnson Nutrition until the company’s acquisition by Reckitt Benckiser and was the past Chairman of the Board of Trustees for the Children’s Museum of Indianapolis.

Categorised in:

This post was written by Michelle LaSpaluto